Top Industry Leaders in the Conjunctivitis Drugs Market
Latest Conjunctivitis Drugs Companies Update
Allergan Received FDA approval for Rexultiยฎ (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.
Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.
Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.
Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.
EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.
List of Conjunctivitis Drugs Key Companies in the Market
- Akorn Pharmaceuticals (US)
- Alcon/Novartis AG (Switzerland)
- Allergan Plc (Ireland)
- Bausch and Lomb (US)
- Actavis Plc (US)
- Pfizer Inc (US)
- Merck and Co. Inc. (US)
- Lupin Limited (India)
- Valeant Pharmaceuticals (Canada)